Literature DB >> 3961896

Factors influencing theophylline disposition in 179 newborns.

J T Gilman, P Gal, R S Levine, C B Hersh, N V Erkan.   

Abstract

The pharmacokinetics of intravenous theophylline were prospectively studied in 179 premature babies. Interrelated variables were analyzed for their influence on theophylline serum clearance. Gestational age, gender, duration of treatment, body weight, and Apgar scores were not found to correlate significantly with theophylline clearance. Weak but statistically significant correlations were found between serum clearance and postnatal (p less than 0.005) and postconceptional age (p less than 0.01). No significant difference in mean serum clearance (Cls) values was found between small-for-gestational-age (SGA) patients (Cls = 17.9 +/- 5.3 ml/kg/h) and appropriate-for-gestational-age (AGA) patients (Cls = 18.8 +/- 5.8 ml/kg/h). Conversely, asphyxiated patients had significantly lower mean clearance values than nonasphyxiated patients (16.4 +/- 5.3 ml/kg/h vs. 20.2 +/- 5.4 ml/kg/h, respectively, p less than 0.001). Volume of distribution for theophylline (n = 147) was 0.77 +/- 0.17 L/kg; there was no significant difference in distribution volumes between asphyxiated and nonasphyxiated patients or between SGA and AGA patients. Step-wise multiple regression analysis revealed postnatal age as the most important determinant of theophylline clearance among the variables analyzed (p less than 0.01). Postconceptional age had a statistically significant association with theophylline clearance in the entire group (n = 179, p less than 0.05). Duration of treatment had a small and statistically borderline effect (p less than 0.10) on theophylline clearance among nonasphyxiated infants when age factors were considered. Analysis of covariance confirmed the statistical effects of both postnatal age and asphyxia on theophylline serum clearance.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3961896     DOI: 10.1097/00007691-198603000-00002

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  9 in total

Review 1.  Neonatal exposure to drugs in breast milk.

Authors:  Patrick J McNamara; Maggie Abbassi
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.200

Review 2.  Therapeutic drug monitoring in the neonate and paediatric age group. Problems and clinical pharmacokinetic implications.

Authors:  J T Gilman
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

Review 3.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Clinical pharmacology of the perinatal period and early infancy.

Authors:  P L Morselli
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

5.  The population pharmacokinetics of theophylline in neonates and young infants.

Authors:  E S Moore; R G Faix; R C Banagale; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1989-02

6.  Dose conversion from aminophylline to theophylline in preterm infants.

Authors:  J Reese; G Prentice; V Y Yu
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1994-07       Impact factor: 5.747

Review 7.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

8.  Population pharmacokinetics of theophylline during paediatric extracorporeal membrane oxygenation.

Authors:  Hussain Mulla; Fazal Nabi; Sanjiv Nichani; Graham Lawson; R K Firmin; David R Upton
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

9.  Theophylline dosing and pharmacokinetics for renal protection in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia.

Authors:  Adam Frymoyer; Krisa P Van Meurs; David R Drover; Jelena Klawitter; Uwe Christians; Valerie Y Chock
Journal:  Pediatr Res       Date:  2020-09-12       Impact factor: 3.756

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.